肝癌组织中浸润树突状细胞的数量和表面分子表达的临床意义  

CLINICAL SIGNIFICANCE OF DENDRITIC CELLS INFILTRATION AND SURFACE MOLECULES EXPRESSION IN HEPATOCELLULAR CARCINOMA

作　　者：罗小玲[1] 葛莲英[1] 谢裕安[1] 匡志鹏[1] 吴继宁[1] 梁安民[1] 王娟[1] 

机构地区：[1]广西医科大学附属肿瘤医院实验研究部,南宁530021

出　　处：《广西医科大学学报》2007年第3期345-348,共4页Journal of Guangxi Medical University

基　　金：国家自然科学基金资助项目(No30360114);广西自然科学基金资助项目(No0448069)

摘　　要：目的:研究人肝癌组织中浸润树突状细胞(DC)的数量和表面分子表达的临床意义。方法:原发性肝细胞癌(肝癌)术后组织标本30例,采用免疫组化方法(即用型两步法SupervisionTM)检测肝癌组织中DC标志蛋白S-100的表达;从肝癌组织中分离浸润性单个核细胞,流式细胞术检测DC的表面分子表达,并用RT-PCR技术检测肝癌组织IL-10、TGF-β1和VEGF-AmRNA。结果:肝癌组织中DC的数量少,高分化肝癌组织中DC浸润数量[(27.22±15.38)个/HPF]高于低分化肝癌[(11.92±8.56)个/HPF](P<0.01);肝癌组织中浸润DC的表面分子如CDla、HLA-DR、CD80、CD86和CD54等MHC-Ⅰ、Ⅱ类分子,共刺激分子和黏附分子存在低表达或不表达,与肝癌的分化程度密切相关。在mRNA水平上,IL-10、TGF-β1和VEGF-A基因在肝癌组织中的表达显著高于正常肝组织(P<0.001,P<0.05)。结论:肝癌组织中浸润DC的数量减少并存在功能缺陷,与肝癌分化程度密切相关。Objective： To investigate the clinical significance of dendritic cells infiltration and surface molecules in human hepatocellular carcinoma （HCC）. Methods： 30 cases of HCC were studied with immunohistochemical staining , surface molecules of infiltrating DC were examined by methods including cells isolation and FACS. Reverse transcript-polymerase chain reaction （RT-PCR） was used to detect IL-10, TGF-β1 and VEGF-A mRNA expression in HCC tissue. Result： The number of infiltrating DC in HCC decreased, and the number of DC infiltration in the group with good differentiationE（27.22±15.38）个/HPF] was significantly higher than that in the group with poor differentiation [（11.92±8.56）个/HPF] （ P 〈0.01）. The levels of some surface molecules such as MHC class Ⅰ （CDla） and Ⅱ （HLA-DR）, and constimulating molecules （CD80, CD86）, and adhesion molecules（CD54） in HCC were down-regulated or negative. In the mRNA level,the expressions of IL-10, TGF-β1 and VEGF-A gene in HCC tissue were higher than those of normal liver tissue（ P 〈0. 001, P 〈0.05）. Conclusion： The infiltrating DC of HCC decreased, and it was a kind of dysfunction DC and was closely linked to differentiation degree of HCC.

关 键 词：肝癌 树突状细胞 细胞表面分子 

分 类 号：R735.7[医药卫生—肿瘤]